Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs

Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering innovative therapies for viral diseases and cancer metastasis, today announced the execution of a second Sponsored Research Agreement with the University of Minnesota's Department of Chemistry to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.